Evidence digest
What the research on Semax actually shows
The indexed literature on Semax includes human clinical or observational records (4 human-clinical or observational records). This digest describes the shape of that evidence and links the records behind it. It does not judge whether Semax is safe or effective for any purpose, and nothing here is medical advice — the material sold by the vendors in this index is labeled for laboratory research use only.
Updated 25 Aug 2026 · 4 studies indexed · 4 human · compound record
- Studies indexed
- 4
- Human evidence
- 4
- Preclinical only
- 0
What is and is not established
What the literature supports
- Human clinical or observational records are indexed for Semax (4).
- Published research is indexed back to 1981, with roughly 230 PubMed records located.
- It is listed by one or more vendors tracked in this index.
What is NOT established
- This index does not evaluate whether Semax is safe or effective for any use.
- Material sold by the vendors indexed here is labeled for laboratory research use only and is not a regulator-approved medicine in that form.
- No dosing, protocol or human-use guidance is provided or implied anywhere in this index.
Studies indexed
4 human — controlled trial
| Study | Evidence type | Model | n | What it reported | Source |
|---|---|---|---|---|---|
| [The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2007 | Human — controlled trial | Not recorded | — | The study of chronic partial denervation (CPD) and quality of life was carried out in 27 patients with definite, probable and possible diagnosis of motor neuron disease (MND) treated with semax (1% solution). The needle electromyography (EMG) was performed thrice with short-term 2 month interval (60 days before enrollment and on day 1 and day 48 of the study) in three muscles on bulbar, cervical and lumbosacral levels on the less affected side. According to Revised El-Escoria… | PMID 18379501 |
| [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 2018 | Human — controlled trial | Not recorded | — | To evaluate the efficacy of semax and timing of rehabilitation on the dynamics of plasma BDNF levels, motor performance, and Barthel index score in patients after ischemic stroke (IS). One hundred and ten patients after IS (43 men, 67 women, mean age 58.0±9.7, Ме 63 years) were examined. All patients were divided into early (89±9 days) and late (214±22 days) rehabilitation groups. Each group was subdivided into semax+ and semax- subgroups. Standard … | PMID 29798983 |
| [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova · 1997 | Human — controlled trial | Not recorded | — | Efficiency of Semax (synthetic derivative of ACTH-4-10) was studied in 30 patients in acute period of hemispherical ischemic stroke. Control group consisted of 80 patients with the strokes analogous in severity and location of the damages and which were treated by conventional therapy. Different clinical rating scales were used for both objectivization of the severity of the patients' state and estimation of the degree of neurological defect. The control of Semax influence on… | PMID 11517472 |
| [Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease]Vestnik oftalmologii · 2000 | Human — controlled trial | Not recorded | — | Semax is a synthetic analog of adrenocorticotropic hormone 4-10 with a pronounced nootropic effect. It was used in the treatment of vascular, toxic allergic, and inflammatory diseases of the optic nerve and partial atrophy of the optic nerve in parallel with basic neurotrophic and antiinflammatory therapy. For evaluating the drug efficiency, the patients were divided into 3 groups, administered the drug via different routes. In group 1 semax was administered intransally as na… | PMID 10741256 |
Vendors listing Semax
The evidence above describes the published literature. What any individual vial contains is a separate question, answered by that vendor’s certificate records rather than by any study on this page.
| Vendor | Score · Coverage | Certificates | |
|---|---|---|---|
| Curo | 93.877% | 1 | profile → |
| Polaris Peptides | 93.877% | 1 | profile → |
| Next Gen Peptides | 93.897% | 1 | profile → |
| Ascend Science | 90.291% | 1 | profile → |
| PeptidePlugs | 89.790% | 4 | profile → |
| Protide Health | 83.994% | 0 | profile → |
| American Peptides | 83.6100% | 2 | profile → |
| Northline Labs | 79.493% | 1 | profile → |
| NeuroLabs Research | 79.386% | 1 | profile → |
| Koi Peptides | 79.394% | 3 | profile → |
| ZC Labs | 79.384% | 1 | profile → |
| Good Science Bio | 79.275% | 0 | profile → |
| Ascension Peptides | 78.186% | 1 | profile → |
| Modern Aminos | 74100% | 2 | profile → |
| Simple Peptide | 7489% | 1 | profile → |
| Vertex Labs | 70.170% | 1 | profile → |
| Improved Peptides | 7089% | 0 | profile → |
| Eternal Peptides | 68.265% | 0 | profile → |
| BioLongevity Labs | 67.274% | 0 | profile → |
| Evolve Peptides | 65.567% | 0 | profile → |
| Mile High Compounds | 65.494% | 0 | profile → |
| Sports Technology Labs | 56.174% | 0 | profile → |
How to read this page
This digest describes what published research exists and what it does not establish. It is not a recommendation, contains no dosing information or protocols, and makes no claim that any compound is safe or effective for any purpose. Material listed by indexed vendors is labeled for laboratory research use only.